nodes	percent_of_prediction	percent_of_DWPC	metapath
Mebendazole—ABCB1—ovarian cancer	0.244	1	CbGaD
Mebendazole—TUBB4B—Vinorelbine—ovarian cancer	0.234	0.375	CbGbCtD
Mebendazole—TUBB4B—Paclitaxel—ovarian cancer	0.164	0.263	CbGbCtD
Mebendazole—TUBB4B—Docetaxel—ovarian cancer	0.119	0.19	CbGbCtD
Mebendazole—ABCB1—Topotecan—ovarian cancer	0.0236	0.0379	CbGbCtD
Mebendazole—ABCB1—Vinorelbine—ovarian cancer	0.0166	0.0267	CbGbCtD
Mebendazole—CYP3A4—Topotecan—ovarian cancer	0.0141	0.0227	CbGbCtD
Mebendazole—ABCB1—Paclitaxel—ovarian cancer	0.0117	0.0188	CbGbCtD
Mebendazole—CYP3A4—Vinorelbine—ovarian cancer	0.00996	0.016	CbGbCtD
Mebendazole—ABCB1—Docetaxel—ovarian cancer	0.00844	0.0136	CbGbCtD
Mebendazole—TUBA1A—oviduct—ovarian cancer	0.0082	0.132	CbGeAlD
Mebendazole—CYP3A4—Paclitaxel—ovarian cancer	0.007	0.0112	CbGbCtD
Mebendazole—ABCB1—Doxorubicin—ovarian cancer	0.00629	0.0101	CbGbCtD
Mebendazole—TUBB4B—oviduct—ovarian cancer	0.00547	0.088	CbGeAlD
Mebendazole—CYP3A4—Docetaxel—ovarian cancer	0.00506	0.00812	CbGbCtD
Mebendazole—CYP3A4—Doxorubicin—ovarian cancer	0.00377	0.00606	CbGbCtD
Mebendazole—TUBA1A—myometrium—ovarian cancer	0.00262	0.0423	CbGeAlD
Mebendazole—TUBA1A—embryo—ovarian cancer	0.00252	0.0406	CbGeAlD
Mebendazole—TUBA1A—epithelium—ovarian cancer	0.00206	0.0332	CbGeAlD
Mebendazole—TUBA1A—uterine cervix—ovarian cancer	0.00204	0.0329	CbGeAlD
Mebendazole—TUBA1A—decidua—ovarian cancer	0.00195	0.0313	CbGeAlD
Mebendazole—TUBA1A—endometrium—ovarian cancer	0.00185	0.0297	CbGeAlD
Mebendazole—TUBB4B—myometrium—ovarian cancer	0.00175	0.0282	CbGeAlD
Mebendazole—TUBA1A—gonad—ovarian cancer	0.00171	0.0276	CbGeAlD
Mebendazole—TUBA1A—uterus—ovarian cancer	0.0017	0.0274	CbGeAlD
Mebendazole—TUBB4B—embryo—ovarian cancer	0.00168	0.0271	CbGeAlD
Mebendazole—TUBA1A—female reproductive system—ovarian cancer	0.00153	0.0246	CbGeAlD
Mebendazole—TUBA1A—bone marrow—ovarian cancer	0.00144	0.0233	CbGeAlD
Mebendazole—TUBA1A—female gonad—ovarian cancer	0.00139	0.0224	CbGeAlD
Mebendazole—TUBA1A—vagina—ovarian cancer	0.00138	0.0223	CbGeAlD
Mebendazole—TUBB4B—uterine cervix—ovarian cancer	0.00136	0.0219	CbGeAlD
Mebendazole—TUBB4B—decidua—ovarian cancer	0.0013	0.0209	CbGeAlD
Mebendazole—TUBA1A—testis—ovarian cancer	0.00123	0.0199	CbGeAlD
Mebendazole—TUBB4B—endometrium—ovarian cancer	0.00123	0.0198	CbGeAlD
Mebendazole—TUBB4B—gonad—ovarian cancer	0.00114	0.0184	CbGeAlD
Mebendazole—TUBB4B—uterus—ovarian cancer	0.00113	0.0183	CbGeAlD
Mebendazole—TUBB4B—female reproductive system—ovarian cancer	0.00102	0.0164	CbGeAlD
Mebendazole—TUBB4B—bone marrow—ovarian cancer	0.000963	0.0155	CbGeAlD
Mebendazole—TUBB4B—female gonad—ovarian cancer	0.000928	0.0149	CbGeAlD
Mebendazole—TUBB4B—vagina—ovarian cancer	0.000922	0.0149	CbGeAlD
Mebendazole—TUBA1A—lymph node—ovarian cancer	0.000895	0.0144	CbGeAlD
Mebendazole—TUBB4B—testis—ovarian cancer	0.000823	0.0133	CbGeAlD
Mebendazole—CYP1A1—epithelium—ovarian cancer	0.000769	0.0124	CbGeAlD
Mebendazole—CYP1A1—uterine cervix—ovarian cancer	0.000762	0.0123	CbGeAlD
Mebendazole—Albendazole—ABCB1—ovarian cancer	0.000678	0.55	CrCbGaD
Mebendazole—Convulsion—Altretamine—ovarian cancer	0.000668	0.0699	CcSEcCtD
Mebendazole—CYP1A1—uterus—ovarian cancer	0.000635	0.0102	CbGeAlD
Mebendazole—TUBB4B—lymph node—ovarian cancer	0.000597	0.00961	CbGeAlD
Mebendazole—CYP1A1—female reproductive system—ovarian cancer	0.000571	0.00919	CbGeAlD
Mebendazole—Ketoprofen—CXCL8—ovarian cancer	0.000554	0.45	CrCbGaD
Mebendazole—CYP1A1—female gonad—ovarian cancer	0.00052	0.00837	CbGeAlD
Mebendazole—CYP1A1—vagina—ovarian cancer	0.000516	0.00832	CbGeAlD
Mebendazole—ABCB1—myometrium—ovarian cancer	0.000509	0.00819	CbGeAlD
Mebendazole—ABCB1—embryo—ovarian cancer	0.000489	0.00788	CbGeAlD
Mebendazole—CYP3A4—female reproductive system—ovarian cancer	0.000419	0.00675	CbGeAlD
Mebendazole—ABCB1—epithelium—ovarian cancer	0.000399	0.00643	CbGeAlD
Mebendazole—ABCB1—uterine cervix—ovarian cancer	0.000396	0.00637	CbGeAlD
Mebendazole—CYP3A4—Liver X Receptor Pathway—FASN—ovarian cancer	0.000392	0.00648	CbGpPWpGaD
Mebendazole—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—ovarian cancer	0.000388	0.00642	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—MUC16—ovarian cancer	0.000383	0.00634	CbGpPWpGaD
Mebendazole—ABCB1—decidua—ovarian cancer	0.000377	0.00607	CbGeAlD
Mebendazole—CYP1A1—Estrogen Receptor Pathway—ESR1—ovarian cancer	0.000369	0.0061	CbGpPWpGaD
Mebendazole—Neutropenia—Chlorambucil—ovarian cancer	0.000368	0.0385	CcSEcCtD
Mebendazole—ABCB1—endometrium—ovarian cancer	0.000358	0.00577	CbGeAlD
Mebendazole—TUBB4B—Centrosome maturation—PPP2R1A—ovarian cancer	0.000352	0.00582	CbGpPWpGaD
Mebendazole—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.000351	0.00581	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—RSF1—ovarian cancer	0.000341	0.00563	CbGpPWpGaD
Mebendazole—CYP1A1—lymph node—ovarian cancer	0.000334	0.00538	CbGeAlD
Mebendazole—ABCB1—gonad—ovarian cancer	0.000332	0.00535	CbGeAlD
Mebendazole—TUBB4B—Parkin-Ubiquitin Proteasomal System pathway—CCNE1—ovarian cancer	0.000331	0.00547	CbGpPWpGaD
Mebendazole—ABCB1—uterus—ovarian cancer	0.00033	0.00531	CbGeAlD
Mebendazole—Neutropenia—Topotecan—ovarian cancer	0.000327	0.0342	CcSEcCtD
Mebendazole—TUBA1A—Pathogenic Escherichia coli infection—CTNNB1—ovarian cancer	0.000325	0.00538	CbGpPWpGaD
Mebendazole—TUBB4B—Regulation of PLK1 Activity at G2/M Transition—PPP2R1A—ovarian cancer	0.000324	0.00535	CbGpPWpGaD
Mebendazole—Neutropenia—Melphalan—ovarian cancer	0.00032	0.0335	CcSEcCtD
Mebendazole—TUBB4B—Pathogenic Escherichia coli infection—TLR4—ovarian cancer	0.000314	0.00519	CbGpPWpGaD
Mebendazole—CYP1A1—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000309	0.00511	CbGpPWpGaD
Mebendazole—ABCB1—female reproductive system—ovarian cancer	0.000297	0.00478	CbGeAlD
Mebendazole—TUBA1A—Cell Cycle—RAD51C—ovarian cancer	0.000296	0.0049	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.00029	0.00479	CbGpPWpGaD
Mebendazole—ABCB1—bone marrow—ovarian cancer	0.00028	0.00451	CbGeAlD
Mebendazole—Neutropenia—Vinorelbine—ovarian cancer	0.00028	0.0293	CcSEcCtD
Mebendazole—Hepatitis—Melphalan—ovarian cancer	0.000274	0.0287	CcSEcCtD
Mebendazole—ABCB1—female gonad—ovarian cancer	0.00027	0.00435	CbGeAlD
Mebendazole—CYP1A1—Oxidative Stress—SOD1—ovarian cancer	0.000268	0.00444	CbGpPWpGaD
Mebendazole—ABCB1—vagina—ovarian cancer	0.000268	0.00432	CbGeAlD
Mebendazole—TUBB4B—Pathogenic Escherichia coli infection—CDH1—ovarian cancer	0.000266	0.0044	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.000266	0.0044	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—PPP1CC—ovarian cancer	0.000259	0.00428	CbGpPWpGaD
Mebendazole—Angioedema—Chlorambucil—ovarian cancer	0.00025	0.0262	CcSEcCtD
Mebendazole—Agranulocytosis—Vinorelbine—ovarian cancer	0.000249	0.0261	CcSEcCtD
Mebendazole—TUBA1A—Metabolism of proteins—INHA—ovarian cancer	0.000247	0.00408	CbGpPWpGaD
Mebendazole—TUBB4B—G2/M Transition—PPP2R1A—ovarian cancer	0.000243	0.00402	CbGpPWpGaD
Mebendazole—CYP1A1—Oxidative Stress—SOD2—ovarian cancer	0.000242	0.00399	CbGpPWpGaD
Mebendazole—TUBB4B—Mitotic G2-G2/M phases—PPP2R1A—ovarian cancer	0.00024	0.00396	CbGpPWpGaD
Mebendazole—ABCB1—testis—ovarian cancer	0.000239	0.00385	CbGeAlD
Mebendazole—TUBA1A—Cell Cycle—RBL2—ovarian cancer	0.000238	0.00393	CbGpPWpGaD
Mebendazole—Convulsion—Chlorambucil—ovarian cancer	0.000237	0.0248	CcSEcCtD
Mebendazole—TUBB4B—Metabolism of proteins—MUC16—ovarian cancer	0.000232	0.00383	CbGpPWpGaD
Mebendazole—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	0.000223	0.00369	CbGpPWpGaD
Mebendazole—Angioedema—Topotecan—ovarian cancer	0.000223	0.0233	CcSEcCtD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000214	0.00354	CbGpPWpGaD
Mebendazole—CYP1A1—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000214	0.00354	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.000214	0.00354	CbGpPWpGaD
Mebendazole—Convulsion—Melphalan—ovarian cancer	0.000207	0.0216	CcSEcCtD
Mebendazole—CYP1A1—Estrogen Receptor Pathway—STAT3—ovarian cancer	0.000207	0.00342	CbGpPWpGaD
Mebendazole—CYP1A1—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.0002	0.00331	CbGpPWpGaD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—ovarian cancer	0.000199	0.00329	CbGpPWpGaD
Mebendazole—TUBA1A—p73 transcription factor network—MYC—ovarian cancer	0.000197	0.00326	CbGpPWpGaD
Mebendazole—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000197	0.00326	CbGpPWpGaD
Mebendazole—TUBB4B—Pathogenic Escherichia coli infection—CTNNB1—ovarian cancer	0.000197	0.00325	CbGpPWpGaD
Mebendazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.000192	0.00318	CbGpPWpGaD
Mebendazole—Angioedema—Vinorelbine—ovarian cancer	0.000191	0.0199	CcSEcCtD
Mebendazole—Neutropenia—Paclitaxel—ovarian cancer	0.000188	0.0197	CcSEcCtD
Mebendazole—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000183	0.0191	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle—RAD51C—ovarian cancer	0.000179	0.00296	CbGpPWpGaD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—ovarian cancer	0.000178	0.00295	CbGpPWpGaD
Mebendazole—Urticaria—Chlorambucil—ovarian cancer	0.000178	0.0186	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000177	0.00293	CbGpPWpGaD
Mebendazole—Abdominal pain—Chlorambucil—ovarian cancer	0.000177	0.0185	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.000175	0.00289	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—TUBB3—ovarian cancer	0.000174	0.00288	CbGpPWpGaD
Mebendazole—ABCB1—lymph node—ovarian cancer	0.000174	0.00279	CbGeAlD
Mebendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000173	0.00286	CbGpPWpGaD
Mebendazole—CYP1A1—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000171	0.00282	CbGpPWpGaD
Mebendazole—Hypersensitivity—Chlorambucil—ovarian cancer	0.000165	0.0172	CcSEcCtD
Mebendazole—Gastrointestinal pain—Topotecan—ovarian cancer	0.000163	0.017	CcSEcCtD
Mebendazole—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	0.000162	0.00267	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.000161	0.00266	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—MLH1—ovarian cancer	0.00016	0.00265	CbGpPWpGaD
Mebendazole—Neutropenia—Docetaxel—ovarian cancer	0.00016	0.0167	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—SKP2—ovarian cancer	0.000158	0.00262	CbGpPWpGaD
Mebendazole—Urticaria—Topotecan—ovarian cancer	0.000158	0.0165	CcSEcCtD
Mebendazole—Abdominal pain—Topotecan—ovarian cancer	0.000157	0.0165	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle—PPP1CC—ovarian cancer	0.000156	0.00259	CbGpPWpGaD
Mebendazole—Urticaria—Melphalan—ovarian cancer	0.000155	0.0162	CcSEcCtD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000154	0.00255	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000153	0.00252	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—INHA—ovarian cancer	0.000149	0.00247	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—ATF3—ovarian cancer	0.000147	0.00243	CbGpPWpGaD
Mebendazole—Hypersensitivity—Topotecan—ovarian cancer	0.000147	0.0153	CcSEcCtD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000146	0.00242	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—RBL2—ovarian cancer	0.000144	0.00237	CbGpPWpGaD
Mebendazole—Hypersensitivity—Melphalan—ovarian cancer	0.000144	0.015	CcSEcCtD
Mebendazole—CYP1A1—PPARA activates gene expression—YAP1—ovarian cancer	0.000143	0.00237	CbGpPWpGaD
Mebendazole—Agranulocytosis—Docetaxel—ovarian cancer	0.000142	0.0149	CcSEcCtD
Mebendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—ovarian cancer	0.00014	0.00232	CbGpPWpGaD
Mebendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.00014	0.00232	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000139	0.0146	CcSEcCtD
Mebendazole—Hepatitis—Docetaxel—ovarian cancer	0.000137	0.0143	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000136	0.00224	CbGpPWpGaD
Mebendazole—Urticaria—Vinorelbine—ovarian cancer	0.000135	0.0142	CcSEcCtD
Mebendazole—Abdominal pain—Vinorelbine—ovarian cancer	0.000135	0.0141	CcSEcCtD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000134	0.00222	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—ovarian cancer	0.000134	0.00221	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CHEK2—ovarian cancer	0.000129	0.00214	CbGpPWpGaD
Mebendazole—Angioedema—Paclitaxel—ovarian cancer	0.000128	0.0134	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000128	0.00212	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000126	0.00208	CbGpPWpGaD
Mebendazole—Rash—Topotecan—ovarian cancer	0.000125	0.0131	CcSEcCtD
Mebendazole—Hypersensitivity—Vinorelbine—ovarian cancer	0.000125	0.0131	CcSEcCtD
Mebendazole—Dermatitis—Topotecan—ovarian cancer	0.000125	0.0131	CcSEcCtD
Mebendazole—Rash—Melphalan—ovarian cancer	0.000123	0.0129	CcSEcCtD
Mebendazole—Dermatitis—Melphalan—ovarian cancer	0.000123	0.0128	CcSEcCtD
Mebendazole—Convulsion—Paclitaxel—ovarian cancer	0.000122	0.0127	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—CCND2—ovarian cancer	0.000121	0.00201	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—BRCA1—ovarian cancer	0.000121	0.00201	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000119	0.00196	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000117	0.00193	CbGpPWpGaD
Mebendazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000116	0.00192	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000116	0.00191	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—PPP2R1A—ovarian cancer	0.000114	0.00189	CbGpPWpGaD
Mebendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.00011	0.00182	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—BRCA2—ovarian cancer	0.00011	0.00181	CbGpPWpGaD
Mebendazole—Neutropenia—Epirubicin—ovarian cancer	0.000108	0.0113	CcSEcCtD
Mebendazole—Rash—Vinorelbine—ovarian cancer	0.000107	0.0112	CcSEcCtD
Mebendazole—Dermatitis—Vinorelbine—ovarian cancer	0.000107	0.0112	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000107	0.00177	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CCNE1—ovarian cancer	0.000106	0.00176	CbGpPWpGaD
Mebendazole—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000105	0.00174	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—TUBB3—ovarian cancer	0.000105	0.00174	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—BIRC5—ovarian cancer	0.000105	0.00173	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—TYMS—ovarian cancer	0.000104	0.00172	CbGpPWpGaD
Mebendazole—Convulsion—Docetaxel—ovarian cancer	0.000103	0.0108	CcSEcCtD
Mebendazole—Neutropenia—Doxorubicin—ovarian cancer	9.96e-05	0.0104	CcSEcCtD
Mebendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—ovarian cancer	9.67e-05	0.0016	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MLH1—ovarian cancer	9.67e-05	0.0016	CbGpPWpGaD
Mebendazole—Agranulocytosis—Epirubicin—ovarian cancer	9.58e-05	0.01	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle—SKP2—ovarian cancer	9.56e-05	0.00158	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—BIRC5—ovarian cancer	9.39e-05	0.00155	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Paclitaxel—ovarian cancer	9.36e-05	0.0098	CcSEcCtD
Mebendazole—Hepatitis—Epirubicin—ovarian cancer	9.21e-05	0.00964	CcSEcCtD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	9.13e-05	0.00151	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	9.13e-05	0.00151	CbGpPWpGaD
Mebendazole—Urticaria—Paclitaxel—ovarian cancer	9.1e-05	0.00952	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—TERT—ovarian cancer	9.09e-05	0.0015	CbGpPWpGaD
Mebendazole—Abdominal pain—Paclitaxel—ovarian cancer	9.05e-05	0.00947	CcSEcCtD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—TERT—ovarian cancer	9.02e-05	0.00149	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	8.94e-05	0.00148	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—ATF3—ovarian cancer	8.87e-05	0.00147	CbGpPWpGaD
Mebendazole—Agranulocytosis—Doxorubicin—ovarian cancer	8.86e-05	0.00927	CcSEcCtD
Mebendazole—Hepatitis—Doxorubicin—ovarian cancer	8.53e-05	0.00892	CcSEcCtD
Mebendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	8.51e-05	0.00141	CbGpPWpGaD
Mebendazole—Hypersensitivity—Paclitaxel—ovarian cancer	8.44e-05	0.00883	CcSEcCtD
Mebendazole—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	8.4e-05	0.00139	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CCND2—ovarian cancer	8.19e-05	0.00135	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Docetaxel—ovarian cancer	7.94e-05	0.00831	CcSEcCtD
Mebendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—ovarian cancer	7.89e-05	0.0013	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CHEK2—ovarian cancer	7.82e-05	0.00129	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	7.73e-05	0.00128	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.72e-05	0.00128	CbGpPWpGaD
Mebendazole—Abdominal pain—Docetaxel—ovarian cancer	7.67e-05	0.00803	CcSEcCtD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	7.59e-05	0.00126	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	7.5e-05	0.00124	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.46e-05	0.00123	CbGpPWpGaD
Mebendazole—CYP1A1—Biological oxidations—CYP1B1—ovarian cancer	7.45e-05	0.00123	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—CYP1B1—ovarian cancer	7.35e-05	0.00121	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CCND2—ovarian cancer	7.33e-05	0.00121	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—BRCA1—ovarian cancer	7.33e-05	0.00121	CbGpPWpGaD
Mebendazole—Rash—Paclitaxel—ovarian cancer	7.22e-05	0.00756	CcSEcCtD
Mebendazole—Dermatitis—Paclitaxel—ovarian cancer	7.21e-05	0.00755	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CCNE1—ovarian cancer	7.18e-05	0.00119	CbGpPWpGaD
Mebendazole—Hypersensitivity—Docetaxel—ovarian cancer	7.15e-05	0.00748	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—TYMS—ovarian cancer	7.05e-05	0.00116	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	6.99e-05	0.00115	CbGpPWpGaD
Mebendazole—Convulsion—Epirubicin—ovarian cancer	6.95e-05	0.00727	CcSEcCtD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	6.93e-05	0.00115	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—PPP2R1A—ovarian cancer	6.91e-05	0.00114	CbGpPWpGaD
Mebendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	6.9e-05	0.00114	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	6.84e-05	0.00113	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	6.83e-05	0.00113	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	6.83e-05	0.00113	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—BRCA2—ovarian cancer	6.63e-05	0.0011	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	6.46e-05	0.00107	CbGpPWpGaD
Mebendazole—Convulsion—Doxorubicin—ovarian cancer	6.43e-05	0.00673	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle—CCNE1—ovarian cancer	6.42e-05	0.00106	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—BIRC5—ovarian cancer	6.34e-05	0.00105	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—TYMS—ovarian cancer	6.3e-05	0.00104	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	6.16e-05	0.00102	CbGpPWpGaD
Mebendazole—Rash—Docetaxel—ovarian cancer	6.12e-05	0.0064	CcSEcCtD
Mebendazole—Dermatitis—Docetaxel—ovarian cancer	6.11e-05	0.0064	CcSEcCtD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	6.01e-05	0.000993	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.89e-05	0.000973	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CCND1—ovarian cancer	5.88e-05	0.000971	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.74e-05	0.000949	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—BIRC5—ovarian cancer	5.67e-05	0.000937	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—MMP2—ovarian cancer	5.66e-05	0.000935	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CDKN1B—ovarian cancer	5.51e-05	0.00091	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—TERT—ovarian cancer	5.49e-05	0.000907	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	5.49e-05	0.000907	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	5.49e-05	0.000907	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Epirubicin—ovarian cancer	5.35e-05	0.0056	CcSEcCtD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	5.31e-05	0.000877	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CCND1—ovarian cancer	5.25e-05	0.000868	CbGpPWpGaD
Mebendazole—Urticaria—Epirubicin—ovarian cancer	5.2e-05	0.00544	CcSEcCtD
Mebendazole—Abdominal pain—Epirubicin—ovarian cancer	5.17e-05	0.00542	CcSEcCtD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	5.14e-05	0.00085	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.95e-05	0.00518	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—MAPK3—ovarian cancer	4.85e-05	0.000801	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	4.85e-05	0.000801	CbGpPWpGaD
Mebendazole—Hypersensitivity—Epirubicin—ovarian cancer	4.82e-05	0.00505	CcSEcCtD
Mebendazole—Urticaria—Doxorubicin—ovarian cancer	4.81e-05	0.00504	CcSEcCtD
Mebendazole—Abdominal pain—Doxorubicin—ovarian cancer	4.79e-05	0.00501	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—MYC—ovarian cancer	4.71e-05	0.000779	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—CXCL8—ovarian cancer	4.7e-05	0.000777	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	4.65e-05	0.000769	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	4.64e-05	0.000767	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—CASP3—ovarian cancer	4.64e-05	0.000766	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—IL2—ovarian cancer	4.63e-05	0.000765	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—MAPK1—ovarian cancer	4.61e-05	0.000762	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	4.54e-05	0.000751	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NME2—ovarian cancer	4.54e-05	0.00075	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	4.5e-05	0.000745	CbGpPWpGaD
Mebendazole—Hypersensitivity—Doxorubicin—ovarian cancer	4.46e-05	0.00467	CcSEcCtD
Mebendazole—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.45e-05	0.000735	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	4.42e-05	0.000731	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—CTNNB1—ovarian cancer	4.34e-05	0.000717	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—MAPK3—ovarian cancer	4.33e-05	0.000716	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—MYC—ovarian cancer	4.21e-05	0.000697	CbGpPWpGaD
Mebendazole—Rash—Epirubicin—ovarian cancer	4.13e-05	0.00432	CcSEcCtD
Mebendazole—Dermatitis—Epirubicin—ovarian cancer	4.12e-05	0.00432	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—MAPK1—ovarian cancer	4.12e-05	0.000682	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	3.94e-05	0.00065	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.85e-05	0.000637	CbGpPWpGaD
Mebendazole—Rash—Doxorubicin—ovarian cancer	3.82e-05	0.004	CcSEcCtD
Mebendazole—Dermatitis—Doxorubicin—ovarian cancer	3.82e-05	0.00399	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	3.72e-05	0.000615	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	3.66e-05	0.000606	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NME2—ovarian cancer	3.63e-05	0.000599	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.61e-05	0.000597	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CCND1—ovarian cancer	3.55e-05	0.000587	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.52e-05	0.000581	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—TP53—ovarian cancer	3.46e-05	0.000572	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	3.44e-05	0.000568	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—MMP2—ovarian cancer	3.42e-05	0.000565	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CDKN1B—ovarian cancer	3.33e-05	0.00055	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	3.25e-05	0.000537	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CCND1—ovarian cancer	3.17e-05	0.000524	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.14e-05	0.000519	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—MAPK3—ovarian cancer	2.93e-05	0.000484	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYTB—ovarian cancer	2.93e-05	0.000484	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	2.9e-05	0.000479	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.86e-05	0.000473	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—MYC—ovarian cancer	2.85e-05	0.00047	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—CXCL8—ovarian cancer	2.84e-05	0.000469	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—MAPK1—ovarian cancer	2.78e-05	0.00046	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—CTNNB1—ovarian cancer	2.62e-05	0.000433	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MAPK3—ovarian cancer	2.62e-05	0.000432	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PPP1CC—ovarian cancer	2.56e-05	0.000423	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—BRIP1—ovarian cancer	2.56e-05	0.000423	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MYC—ovarian cancer	2.55e-05	0.000421	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.52e-05	0.000417	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MAPK1—ovarian cancer	2.49e-05	0.000412	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.35e-05	0.000388	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYTB—ovarian cancer	2.34e-05	0.000386	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.34e-05	0.000386	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.29e-05	0.000378	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.27e-05	0.000374	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NME2—ovarian cancer	2.23e-05	0.000369	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.23e-05	0.000368	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.21e-05	0.000365	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.15e-05	0.000355	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—TP53—ovarian cancer	2.09e-05	0.000345	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—BRIP1—ovarian cancer	2.04e-05	0.000338	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.04e-05	0.000338	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.94e-05	0.000321	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.86e-05	0.000308	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.84e-05	0.000304	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.79e-05	0.000295	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.75e-05	0.000289	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.75e-05	0.000289	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—YAP1—ovarian cancer	1.72e-05	0.000284	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.7e-05	0.000281	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.65e-05	0.000273	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.52e-05	0.000251	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.49e-05	0.000247	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.47e-05	0.000243	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYTB—ovarian cancer	1.44e-05	0.000238	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—FASN—ovarian cancer	1.4e-05	0.000231	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC5A5—ovarian cancer	1.38e-05	0.000227	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—YAP1—ovarian cancer	1.37e-05	0.000226	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC2A1—ovarian cancer	1.33e-05	0.00022	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.3e-05	0.000215	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP1B1—ovarian cancer	1.27e-05	0.000211	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.26e-05	0.000208	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.26e-05	0.000208	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.24e-05	0.000205	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	1.13e-05	0.000187	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.12e-05	0.000186	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—FASN—ovarian cancer	1.12e-05	0.000185	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.1e-05	0.000182	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.06e-05	0.000175	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ABCB1—ovarian cancer	1.05e-05	0.000173	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—TYMS—ovarian cancer	1.03e-05	0.00017	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.02e-05	0.000168	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PPP2R1A—ovarian cancer	9.02e-06	0.000149	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—YAP1—ovarian cancer	8.44e-06	0.00014	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CAV1—ovarian cancer	8.3e-06	0.000137	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—TYMS—ovarian cancer	8.23e-06	0.000136	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.93e-06	0.000131	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CG—ovarian cancer	7.56e-06	0.000125	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—FASN—ovarian cancer	6.88e-06	0.000114	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC5A5—ovarian cancer	6.77e-06	0.000112	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CD—ovarian cancer	6.65e-06	0.00011	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CAV1—ovarian cancer	6.63e-06	0.00011	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC2A1—ovarian cancer	6.54e-06	0.000108	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.27e-06	0.000104	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CG—ovarian cancer	6.04e-06	9.98e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CB—ovarian cancer	5.79e-06	9.57e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.56e-06	9.19e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CD—ovarian cancer	5.31e-06	8.77e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.16e-06	8.53e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—TYMS—ovarian cancer	5.07e-06	8.38e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTEN—ovarian cancer	5.01e-06	8.27e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.63e-06	7.65e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CAV1—ovarian cancer	4.08e-06	6.75e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTEN—ovarian cancer	4e-06	6.61e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.72e-06	6.15e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CA—ovarian cancer	3.53e-06	5.84e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.27e-06	5.41e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—AKT1—ovarian cancer	2.89e-06	4.77e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.85e-06	4.71e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.82e-06	4.66e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTEN—ovarian cancer	2.46e-06	4.07e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—AKT1—ovarian cancer	2.3e-06	3.81e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.74e-06	2.87e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—AKT1—ovarian cancer	1.42e-06	2.35e-05	CbGpPWpGaD
